We are live on ! Find out more
BOCH

Blue Owl Capital Holdings Portfolio holdings

AUM $372M
1-Year Est. Return 78.25%
This Fund
S&P 500
This Quarter Est. Return
-13.36%
1 Year Est. Return
+78.25%
3 Year Est. Return
+112.77%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$360M
AUM Growth
-$141M
Cap. Flow
-$61.4M
Cap. Flow %
-17.07%
Top 10 Hldgs %
67.99%
Holding
55
New
10
Increased
7
Reduced
8
Closed
14

Top Buys

Rank Stock Value
1
CNTX icon
Context Therapeutics
CNTX
+$8.9M
2
VKTX icon
Viking Therapeutics
VKTX
+$6.23M
3
DM
Desktop Metal, Inc.
DM
+$4.62M
4
STWD icon
Starwood Property Trust
STWD
+$4.41M
5
PYXS icon
Pyxis Oncology
PYXS
+$4.4M

Top Sells

Rank Stock Value
1
HOOD icon
Robinhood
HOOD
+$54M
2
CGEM icon
Cullinan Oncology
CGEM
+$18.6M
3
MLTX icon
MoonLake Immunotherapeutics
MLTX
+$5.02M
4
DELL icon
Dell
DELL
+$4.71M
5
LABD icon
Direxion Daily S&P Biotech Bear 3X ETF
LABD
+$3.57M

Sector Composition

Rank Sector Weight
1 Healthcare 71.57%
2 Technology 17.92%
3 Financials 8.96%
4 Real Estate 1.19%
5 Industrials 0.09%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CGEM icon
1
Cullinan Oncology
CGEM
$1.07B
$35.7M 9.94%
2,049,172
-875,670
-30% -$18.6M
PLRX icon
2
Pliant Therapeutics
PLRX
$66.3M
$32.3M 8.98%
3,004,199
– –
OBDC icon
3
Blue Owl Capital
OBDC
$5.47B
$31.4M 8.74%
2,045,070
– –
KVYO icon
4
Klaviyo
KVYO
$5.65B
$29.8M 8.29%
1,198,270
– –
LRMR icon
5
Larimar Therapeutics
LRMR
$398M
$28M 7.78%
3,859,468
-135,000
-3% -$1.03M
ENGN icon
6
enGene Therapeutics
ENGN
$118M
$23.1M 6.43%
2,449,827
-11,523
-0.5% -$148K
TRML
7
DELISTED
Tourmaline Bio
TRML
$22.1M 6.14%
1,715,401
+268,000
+19% +$4.31M
EVCM icon
8
EverCommerce
EVCM
$2.12B
$18M 5.01%
1,641,929
– –
SLRN
9
DELISTED
ACELYRIN
SLRN
$12.9M 3.59%
2,926,028
+100,000
+4% +$469K
RPTX
10
DELISTED
Repare Therapeutics
RPTX
$11.1M 3.1%
3,372,499
+250,000
+8% +$892K
RARE icon
11
Ultragenyx Pharmaceutical
RARE
$2.56B
$11M 3.07%
268,238
– –
CNTX icon
12
Context Therapeutics
CNTX
$54.3M
$10.3M 2.88%
+5,161,290
New +$8.9M
IRON icon
13
Disc Medicine
IRON
$2.85B
$9.7M 2.7%
215,260
+60,000
+39% +$2.04M
TOST icon
14
Toast
TOST
$18.8B
$8.31M 2.31%
322,578
– –
ETWO
15
DELISTED
E2open Parent Holdings
ETWO
$7.41M 2.06%
1,650,943
– –
KROS icon
16
Keros Therapeutics
KROS
$199M
$7.2M 2%
157,633
-15,000
-9% -$806K
IMA
17
ImageneBio Inc
IMA
$65.5M
$6.75M 1.88%
340,927
+16,667
+5% +$294K
SGMT icon
18
Sagimet Biosciences
SGMT
$449M
$5.72M 1.59%
1,673,877
– –
MLYS icon
19
Mineralys Therapeutics
MLYS
$2.38B
$5.27M 1.47%
450,339
-90,741
-17% -$1.14M
VKTX icon
20
Viking Therapeutics
VKTX
$3.93B
$5.04M 1.4%
+95,000
New +$6.23M
INZY
21
DELISTED
Inozyme Pharma
INZY
$5M 1.39%
1,120,027
-150,000
-12% -$727K
STWD icon
22
Starwood Property Trust
STWD
$6.18B
$4.29M 1.19%
+226,456
New +$4.41M
PYXS icon
23
Pyxis Oncology
PYXS
$184M
$3.46M 0.96%
+1,046,025
New +$4.4M
MREO
24
Mereo BioPharma
MREO
$49.4M
$3.23M 0.9%
+897,809
New +$2.91M
AQST icon
25
Aquestive Therapeutics
AQST
$472M
$2.96M 0.82%
1,140,000
+265,000
+30% +$885K
1
2 3

Similar funds

PC
Promethos Capital Boston, Massachusetts $372M AUM 23.19% 1-Year Est. Return
GIP
Gavilan Investment Partners Burlingame, California $372M AUM 6.04% 1-Year Est. Return
DPCM
Doma Perpetual Capital Management Miami, Florida $372M AUM 14.96% 1-Year Est. Return
SAAM
Solus Alternative Asset Management Summit, New Jersey $372M AUM 45.33% 1-Year Est. Return
MWM
Mindset Wealth Management Indianapolis, Indiana $372M AUM 50.62% 1-Year Est. Return
AWA
Acumen Wealth Advisors Chattanooga, Tennessee $372M AUM
KP
Kiltearn Partners Edinburgh, United Kingdom $372M AUM 18.16% 1-Year Est. Return
TCM
Thomist Capital Management Houston, Texas $371M AUM 77.62% 1-Year Est. Return

Blue Owl Capital Holdings's Q2 2024 Portfolio in Review

As of Q2 2024, Blue Owl Capital Holdings held 55 positions worth $360M, down 28% from $501M the previous quarter. Its ten largest holdings account for 68% of the portfolio.

Blue Owl Capital Holdings withdrew a net $61.4M in Q2 2024, closing 14 positions and reducing 8 holdings. Its most notable exit was Robinhood, an estimated $54M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 72% of assets, up from 67% a quarter earlier, followed by Technology and Financials.

Against the trend, Blue Owl Capital Holdings opened a new position in Context Therapeutics worth $10.3M.

  • Blue Owl Capital Holdings's largest Q2 2024 buy was Context Therapeutics: 5,161,290 shares worth $10.3M.
  • Blue Owl Capital Holdings added most to Desktop Metal, Inc. in Q2 2024, an estimated $4.62M increase.
  • Blue Owl Capital Holdings's biggest Q2 2024 reduction was Cullinan Oncology, cutting an estimated $18.6M.
  • Blue Owl Capital Holdings fully exited Robinhood in Q2 2024, selling an estimated $54M.
  • Blue Owl Capital Holdings's ten largest holdings make up 68% of its $360M portfolio in Q2 2024.
  • Blue Owl Capital Holdings opened 10 new positions and closed 14 in Q2 2024.
  • Blue Owl Capital Holdings's portfolio value fell 28% quarter-over-quarter to $360M.

Based on Blue Owl Capital Holdings's 13F filing for Q2 2024, filed 15 Aug 2024.